PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPemetrexed
Alimta(pemetrexed)
Alimta, Armisarte, Axtle, Ciambra, Pemetrexed, Pemfexy (pemetrexed) is a small molecule pharmaceutical. Pemetrexed was first approved as Alimta on 2004-02-04. It is used to treat mesothelial neoplasms and non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat mesothelioma and non-small-cell lung carcinoma. The pharmaceutical is active against dihydrofolate reductase. In addition, it is known to target proton-coupled folate transporter, thymidylate synthase, and trifunctional purine biosynthetic protein adenosine-3.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Alimta, Pemetrexed, Pemfexy (discontinued: Pemetrexed, Pemetrexed ditromethamine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pemetrexed disodium
Tradename
Company
Number
Date
Products
PEMETREXED DISODIUMHospiraN-214218 RX2022-06-22
3 products, RLD, RS
ALIMTAEli LillyN-021462 RX2004-02-04
2 products, RLD, RS
PEMETREXED DISODIUMSandozN-214657 RX2022-05-26
3 products, RLD, RS
PEMETREXEDShilpa MedicareN-215179 RX2023-05-22
3 products, RLD, RS
Show 1 discontinued
Pemetrexed
Tradename
Company
Number
Date
Products
PEMETREXEDAllerganN-208419 RX2020-08-21
3 products, RLD, RS
PEMFEXYEagle PharmaceuticalsN-209472 RX2020-02-08
1 products, RLD, RS
Pemetrexed ditromethamine
Tradename
Company
Number
Date
Products
PEMETREXED DITROMETHAMINEHospiraN-208746 DISCN2022-06-10
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
alimtaNew Drug Application2023-05-19
axtleNew Drug Application2025-10-08
pemetrexedANDA2025-12-23
pemetrexed dipotassiumNew Drug Application2025-02-05
pemetrexed disodiumANDA2022-11-15
pemetrexed pemetrexedANDA2025-04-01
pemfexyNew Drug Application2023-05-15
pemrydi rtuNew Drug Application2025-07-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
mesothelial neoplasms—D018301—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Pemetrexed, Pemfexy, Eagle Pharms
96049902035-10-28DP
Pemetrexed Disodium, Pemetrexed, Shilpa
111478172035-03-26DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BA: Folic acid analogs, antimetabolites
— L01BA04: Pemetrexed
HCPCS
Code
Description
J9304
Injection, pemetrexed (pemfexy), 10 mg
J9305
Injection, pemetrexed, not otherwise specified, 10 mg
Clinical
Clinical Trials
1454 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289——1361182287
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175—C34.906288—342
NeoplasmsD009369—C801282——20
Neoplasm metastasisD009362EFO_0009708—472——13
MesotheliomaD008654—C45361—19
Head and neck neoplasmsD006258——251——8
Small cell lung carcinomaD055752——251——7
RecurrenceD012008——141——6
Pancreatic neoplasmsD010190EFO_0003860C25241——6
Neoplasms by siteD009371———11——2
Respiratory tract diseasesD012140————1——1
Show 7 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50515———17
Ovarian neoplasmsD010051EFO_0003893C5647———9
Colorectal neoplasmsD015179——55———8
Malignant mesotheliomaD000086002——23——15
CarcinomaD002277—C80.014———4
Endometrial neoplasmsD016889EFO_0004230—32———4
Small cell carcinomaD018288——13———3
Stomach neoplasmsD013274EFO_0003897C1613———3
Uterine neoplasmsD014594EFO_0003859C55—3———3
Urologic neoplasmsD014571—C64-C6813———3
Show 37 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliomaD005910EFO_0000520—1————1
ChordomaD002817EFO_0000334—1————1
Squamous cell carcinoma of head and neckD000077195——1————1
Squamous cell neoplasmsD018307——1————1
Non-hodgkin lymphomaD008228—C85.91————1
Central nervous system neoplasmsD016543——1————1
LymphomaD008223—C85.91————1
Sezary syndromeD012751—C84.11————1
Mycosis fungoidesD009182—C84.01————1
T-cell lymphoma cutaneousD016410—C84.A1————1
Show 5 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePemetrexed
INNpemetrexed
Description
Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..
Classification
Small molecule
Drug classantineoplastic thymidylate synthetase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1
Identifiers
PDB—
CAS-ID137281-23-3
RxCUI—
ChEMBL IDCHEMBL225072
ChEBI ID63616
PubChem CID446556
DrugBankDB00642
UNII ID04Q9AIZ7NO (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Alimta – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Pemfexy – Eagle Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 25,889 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
33,391 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use